

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claims 1-6 (canceled).**

**Claim 7 (previously presented):** A method for treating fibromyalgia in a mammal, the method comprising administering to said mammal a therapeutically effective amount for treating fibromyalgia of (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid or a pharmaceutically acceptable salt thereof.

**Claim 8 (canceled).**

**Claim 9 (previously presented):** A method for treating fibromyalgia and a concomitant disorder in a mammal, the method comprising administering to said mammal a therapeutically effective amount for treating fibromyalgia and a concomitant disorder of (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid or a pharmaceutically acceptable salt thereof wherein-said concomitant disorder is selected from migraine headaches, temporomandibular joint dysfunction, dysautonomia, endocrine dysfunction, dizziness, cold intolerance, chemical sensitivity, sicca symptoms, cognitive dysfunction, generalized anxiety disorder, premenstrual dysphoric dysthemia, irritable bowel syndrome, functional abdominal pain, neuropathic pain, and somatoform disorders, OCD, phobias, and PTSD.

**Claim 10 (canceled).**

**Claim 11 (previously presented):** The method according to claim 9 wherein said concomitant disorder is generalized anxiety disorder, premenstrual dysphoric disorder, or a somatoform disorder.

**Claim 12 (previously presented):** The method according to 9 wherein said concomitant disorder is irritable bowel syndrome, functional abdominal pain, neuropathic pain, or migraine headache.

**Claims 13-16 (canceled).**